PHVS Pharvaris NV

Pharvaris to Participate in BioCapital Europe

Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Participation Details:

Title: “Shaping the New Biotech Reality – Key Lessons from COVID” Panel Presentation

Date/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST)

Title: Pharvaris Corporate Presentation

Date/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST)

The virtual presentation will be available for 30 days on the Pharvaris website at .

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit .

Investor Contact

Chad Rubin, Solebury Trout

Media Contact

Maggie Beller, Russo Partners, LLC





EN
04/03/2021

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Lewi
PROX PROXIMUS SA DE DROIT PUBLIC
MTLS MATERIALISE ADS
COFB COFINIMMO SA
ELI ELIA GROUP SA/NV
WDP WAREHOUSES DE PAUW SCA
PHVS PHARVARIS NV
07/25/25 July 25, 2025 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering ...

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previ...

July 24, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
PHVS PHARVARIS NV

Pharvaris Raises $ 175m in gross proceeds via public offering

Pharvaris announced the pricing of an upsized public offering of 8,250,000 ordinary shares at a price of $ 20 per share (13.49% discount to previous close), and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $ 19.99 per pre-funded warrant for gross proceeds of approx. $ 175m. We expect the net proceeds to extend Pharvaris' cash runway to mid-2027 (KBCSe) from 2H26, and will be used for R&D as well as commercialisation preparations in the US. We update our ...

07/23/25 July 23, 2025 1 EN
Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
KPN ROYAL KPN NV
RAND RANDSTAD NV ... (+8)

Morning Notes : AVS NA, CSUA NA, GIMBb BB, KPNa NA, RANDa NA, SOFb BB,...

: AVS NA, CSUA NA, GIMBb BB, KPNa NA, RANDa NA, SOFb BB, N4SA NA, PHVS US

KPN ROYAL KPN NV
RAND RANDSTAD NV
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
GIMB GIMV NV
CSM CORBION NV
PHVS PHARVARIS NV
ECMPA EUROCOMMERCIAL PROPERTIES NV
07/23/25 July 23, 2025 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of...

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20...

July 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch